ARTICLE | Clinical News
SYL040012: Phase II started
June 18, 2012 7:00 AM UTC
Sylentis said it began a placebo-controlled, dose-ranging, European Phase II trial to evaluate daily SYL040012 eye drops for 14 days in 80 patients. Sylentis is a subsidiary of Zeltia S.A. (Madrid:ZE...